Research ExplorerPublicationsSorafenib sensitizes head and neck squamous cell carcinoma c...

Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation

Standard

Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. / Laban, Simon; Steinmeister, Leonhard; Gleißner, Lisa; Grob, Tobias J; Grénman, Reidar; Petersen, Cordula; Gal, Andreas; Knecht, Rainald; Dikomey, Ekkehard; Kriegs, Malte.

In: RADIOTHER ONCOL, Vol. 109, No. 2, 01.11.2013, p. 286-92.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Laban, S, Steinmeister, L, Gleißner, L, Grob, TJ, Grénman, R, Petersen, C, Gal, A, Knecht, R, Dikomey, E & Kriegs, M 2013, 'Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation', RADIOTHER ONCOL, vol. 109, no. 2, pp. 286-92. https://doi.org/10.1016/j.radonc.2013.07.003

APA

Laban, S., Steinmeister, L., Gleißner, L., Grob, T. J., Grénman, R., Petersen, C., Gal, A., Knecht, R., Dikomey, E., & Kriegs, M. (2013). Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. RADIOTHER ONCOL, 109(2), 286-92. https://doi.org/10.1016/j.radonc.2013.07.003

Vancouver

Laban S, Steinmeister L, Gleißner L, Grob TJ, Grénman R, Petersen C et al. Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. RADIOTHER ONCOL. 2013 Nov 1;109(2):286-92. https://doi.org/10.1016/j.radonc.2013.07.003

Bibtex

@article{0fa54743e7974f95a815af4abf775e88,
title = "Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation",
abstract = "BACKGROUND AND PURPOSE: There is a great need to improve the outcome of locoregionally advanced squamous cell carcinomas of the head and neck (HNSCC). Standard treatment includes a combination of surgery, radio- and chemotherapy. The addition of molecular targeting agents to conventional treatment may improve outcomes. In this study the Raf inhibitor sorafenib was used to increase the radiosensitivity of HNSCC cell lines.MATERIAL AND METHODS: In a panel of six cell lines (A549, FaDu, UTSCC 60A, UTSCC 42A, UTSCC 42B, UTSCC 29) radiosensitivity was measured by colony formation assay and apoptosis and cell cycle analysis were performed by flow cytometry. DNA repair was analyzed by 53BP1 immunohistochemistry.RESULTS: Sorafenib added prior to irradiation resulted in an increased cellular radiosensitivity (DEF0.5=1.11-1.84). Radiosensitization was not caused by an enhanced rate of apoptosis or cell cycle effects. In contrast, sorafenib was shown for the first time to block the repair of DNA double-strand breaks (DSB).CONCLUSION: Our data suggest that sorafenib may be used to overcome the radioresistance of HNSCC through the inhibition of DSB repair.",
author = "Simon Laban and Leonhard Steinmeister and Lisa Glei{\ss}ner and Grob, {Tobias J} and Reidar Gr{\'e}nman and Cordula Petersen and Andreas Gal and Rainald Knecht and Ekkehard Dikomey and Malte Kriegs",
note = "Copyright {\textcopyright} 2013 Elsevier Ireland Ltd. All rights reserved.",
year = "2013",
month = nov,
day = "1",
doi = "10.1016/j.radonc.2013.07.003",
language = "English",
volume = "109",
pages = "286--92",
journal = "RADIOTHER ONCOL",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation

AU - Laban, Simon

AU - Steinmeister, Leonhard

AU - Gleißner, Lisa

AU - Grob, Tobias J

AU - Grénman, Reidar

AU - Petersen, Cordula

AU - Gal, Andreas

AU - Knecht, Rainald

AU - Dikomey, Ekkehard

AU - Kriegs, Malte

N1 - Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - BACKGROUND AND PURPOSE: There is a great need to improve the outcome of locoregionally advanced squamous cell carcinomas of the head and neck (HNSCC). Standard treatment includes a combination of surgery, radio- and chemotherapy. The addition of molecular targeting agents to conventional treatment may improve outcomes. In this study the Raf inhibitor sorafenib was used to increase the radiosensitivity of HNSCC cell lines.MATERIAL AND METHODS: In a panel of six cell lines (A549, FaDu, UTSCC 60A, UTSCC 42A, UTSCC 42B, UTSCC 29) radiosensitivity was measured by colony formation assay and apoptosis and cell cycle analysis were performed by flow cytometry. DNA repair was analyzed by 53BP1 immunohistochemistry.RESULTS: Sorafenib added prior to irradiation resulted in an increased cellular radiosensitivity (DEF0.5=1.11-1.84). Radiosensitization was not caused by an enhanced rate of apoptosis or cell cycle effects. In contrast, sorafenib was shown for the first time to block the repair of DNA double-strand breaks (DSB).CONCLUSION: Our data suggest that sorafenib may be used to overcome the radioresistance of HNSCC through the inhibition of DSB repair.

AB - BACKGROUND AND PURPOSE: There is a great need to improve the outcome of locoregionally advanced squamous cell carcinomas of the head and neck (HNSCC). Standard treatment includes a combination of surgery, radio- and chemotherapy. The addition of molecular targeting agents to conventional treatment may improve outcomes. In this study the Raf inhibitor sorafenib was used to increase the radiosensitivity of HNSCC cell lines.MATERIAL AND METHODS: In a panel of six cell lines (A549, FaDu, UTSCC 60A, UTSCC 42A, UTSCC 42B, UTSCC 29) radiosensitivity was measured by colony formation assay and apoptosis and cell cycle analysis were performed by flow cytometry. DNA repair was analyzed by 53BP1 immunohistochemistry.RESULTS: Sorafenib added prior to irradiation resulted in an increased cellular radiosensitivity (DEF0.5=1.11-1.84). Radiosensitization was not caused by an enhanced rate of apoptosis or cell cycle effects. In contrast, sorafenib was shown for the first time to block the repair of DNA double-strand breaks (DSB).CONCLUSION: Our data suggest that sorafenib may be used to overcome the radioresistance of HNSCC through the inhibition of DSB repair.

U2 - 10.1016/j.radonc.2013.07.003

DO - 10.1016/j.radonc.2013.07.003

M3 - SCORING: Journal article

C2 - 23953412

VL - 109

SP - 286

EP - 292

JO - RADIOTHER ONCOL

JF - RADIOTHER ONCOL

SN - 0167-8140

IS - 2

ER -